• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by Zivo Bioscience Inc.

    4/26/24 8:05:12 AM ET
    $ZIVO
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ZIVO alert in real time by email
    DEFA14A 1 zivo_defa14a.htm DEFA14A zivo_defa14a.htm

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 14A

     

    Proxy Statement Pursuant to Section 14(a) of

    the Securities Exchange Act of 1934 (Amendment No.)

     

    ☒

    Filed by the Registrant

     

     

    ☐

    Filed by a Party other than the Registrant

     

     

    Check the appropriate box:

     

     

    ☐

    Preliminary Proxy Statement

     

     

    ☐

    Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

     

     

    ☐

    Definitive Proxy Statement

     

     

    ☒

    Definitive Additional Materials

     

     

    ☐

    Soliciting Material Under §240.14a-12

     

    Zivo Bioscience, Inc.

    (Name of Registrant as Specified In Its Charter)

     

    (Name of Person(s) Filing Proxy Statement, if other than the Registrant)

     

    Payment of Filing Fee (Check all boxes that apply):

     

    ☒

    No fee required.

     

     

    ☐

    Fee paid previously with preliminary materials.

     

     

    ☐

    Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11.

     

     

     

      

     

    ZIVO BIOSCIENCES, INC.

    CONTROL ID:

     

    REQUEST ID:

     

     

     

    IMPORTANT NOTICE REGARDING THE AVAILABILITY OF PROXY MATERIALS

    FOR THE ANNUAL MEETING OF STOCKHOLDERS

     

     

    DATE:

    TUESDAY, JUNE 11, 2024

     

    TIME:

    10:00 A.M. EASTERN TIME

     

    LOCATION:

    3600 CENTERPOINT PARKWAY, PONTIAC, MI 48341

     

     

     

    HOW TO REQUEST PAPER COPIES OF OUR MATERIALS

    PHONE:

    CALL TOLL FREE

    1-866-752-8683

    FAX:

    SEND THIS CARD TO

    202-521-3464

    INTERNET:

    HTTPS://WWW.IPROXYDIRECT.COM/ZIVO
    AND FOLLOW THE ON-SCREEN INSTRUCTIONS.

    EMAIL:

    [email protected]

    INCLUDE YOUR CONTROL ID IN YOUR EMAIL.

     

     

    THIS COMMUNICATION REPRESENTS A NOTICE TO ACCESS A MORE COMPLETE SET OF PROXY MATERIALS AVAILABLE TO YOU ON THE INTERNET. THE PROXY MATERIALS INCLUDE THIS NOTICE, PROXY STATEMENT, AND 2023 ANNUAL REPORT TO THE SHAREHOLDERS. WE ENCOURAGE YOU TO ACCESS AND REVIEW ALL OF THE IMPORTANT INFORMATION CONTAINED IN THE PROXY MATERIALS BEFORE VOTING. THE PROXY MATERIALS ARE AVAILABLE AT: HTTPS://WWW.IPROXYDIRECT.COM/ZIVO

     

    IF YOU WANT TO RECEIVE A PAPER COPY OF THE PROXY MATERIALS YOU MUST REQUEST ONE. THERE IS NO CHARGE TO YOU FOR REQUESTING A COPY.  TO FACILITATE TIMELY DELIVERY PLEASE MAKE THE REQUEST, AS INSTRUCTED ABOVE, BEFORE MAY 30, 2024.

     

    YOU MAY ENTER YOUR VOTING INSTRUCTIONS AT HTTPS://WWW.IPROXYDIRECT.COM/CPE

    UNTIL 11:59 PM EASTERN TIME JUNE 10, 2024.

     

     

     

    THE PURPOSES OF THIS MEETING ARE AS FOLLOWS:

     

     

     

     

     

    1. TO ELECT ONE CLASS II DIRECTOR TO HOLD OFFICE UNTIL THE 2027 ANNUAL MEETING OF SHAREHOLDERS;


    2. TO RATIFY THE APPOINTMENT OF OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE FISCAL YEAR ENDING DECEMBER 31, 2024; AND


    3. TO APPROVE (ON AN ADVISORY BASIS) THE COMPENSATION OF OUR NAMED EXECUTIVE OFFICERS.

     

     

     

     

     

     

    PURSUANT TO SECURITIES AND EXCHANGE COMMISSION RULES, YOU ARE RECEIVING THIS NOTICE THAT THE PROXY MATERIALS FOR THE ANNUAL MEETING ARE AVAILABLE ON THE INTERNET. FOLLOW THE INSTRUCTIONS ABOVE TO VIEW THE MATERIALS AND VOTE OR REQUEST PRINTED COPIES.
    THE BOARD OF DIRECTORS HAS FIXED THE CLOSE OF BUSINESS ON APRIL 12, 2024  AS THE RECORD DATE FOR THE DETERMINATION OF STOCKHOLDERS ENTITLED TO RECEIVE NOTICE OF THE ANNUAL MEETING AND TO VOTE THE SHARES OF OUR COMMON STOCK, PAR VALUE $.001 PER SHARE, THEY HELD ON THAT DATE AT THE MEETING OR ANY POSTPONEMENT OR ADJOURNMENT OF THE MEETING.

     

    THE BOARD OF DIRECTORS RECOMMENDS THAT YOU VOTE ‘FOR’ ALL PROPOSALS ABOVE.

     

    PLEASE NOTE - THIS IS NOT A PROXY CARD - YOU CANNOT VOTE BY RETURNING THIS CARD

     

     
    2

     

     

    ZIVO BIOSCIENCES, INC.

    SHAREHOLDER SERVICES

    1 Glenwood Avenue Suite 1001

    Raleigh NC 27603

     

    FIRST-CLASS MAIL

    US POSTAGE

    PAID

    RALEIGH NC

    PERMIT # 870

     

    TIME SENSITIVE SHAREHOLDER INFORMATION ENCLOSED

     

    IMPORTANT SHAREHOLDER INFORMATION

     

    YOUR VOTE IS IMPORTANT

     

     
    3

     

    Get the next $ZIVO alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ZIVO

    DatePrice TargetRatingAnalyst
    12/15/2021$9.00Buy
    Maxim Group
    More analyst ratings

    $ZIVO
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    ZIVO Bioscience CEO Letter to Shareholders Highlights Progress with Human Nutrition and Animal Therapeutic Businesses

    ZIVO Bioscience, Inc. (OTCQB:ZIVO), a biotech and agtech R&D company engaged in the development of therapeutic and nutritional products derived from proprietary algal cultures, today issued the following letter to shareholders from Chairman, President and Chief Executive Officer John B. Payne. Dear Fellow Shareholders, I am pleased to provide you with this important update on the significant progress by ZIVO Bioscience and a review of our exciting future direction. Quite simply, this past year has been one of the most pivotal in our history. Our proprietary algae platform has delivered breakthrough results that position ZIVO at the forefront of two rapidly growing markets – human nutrit

    9/10/25 8:30:00 AM ET
    $ZIVO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ZIVO Bioscience and Leading Global Animal Health Company to Advance ZIVO's Immune-Enhancing Compounds in Poultry

    ZIVO Bioscience, Inc. (OTCQB:ZIVO), a biotech and agtech R&D company engaged in the development of therapeutic and nutritional products derived from proprietary algal cultures, announces it has entered into a relationship with one of the world's leading animal health companies to advance ZIVO's novel immune-boosting compounds for use in multiple poultry market segments. The collaboration is expected to expand over time to address significant unmet needs in other livestock and companion animal species. Initially, ZIVO and its partner have executed two agreements that will govern independent studies designed to validate and expand the use of ZIVO's proprietary actives as immune-enhancing bi

    6/20/25 8:00:00 AM ET
    $ZIVO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    University of Delaware Study Identifies Optimal Formulation of ZIVO's Active Ingredients for Further Testing to Mitigate Avian Influenza in Poultry

    ZIVO Bioscience, Inc. (OTCQB:ZIVO), a pioneering biotech/agtech R&D company dedicated to developing therapeutic, medicinal and nutritional product candidates derived from proprietary algal cultures, today announced positive results from its second collaborative study with the University of Delaware evaluating the efficacy of several formulations of ZIVO's proprietary active ingredients in mitigating the spread of Low Pathogenicity Avian Influenza (LPAI) virus among poultry. Building upon the outcomes of the initial study, this second study aimed to assess and compare the performance of three different ZIVO formulations in both directly challenged and contact-exposed birds. The study affirm

    5/6/25 5:54:00 PM ET
    $ZIVO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ZIVO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Maxim Group initiated coverage on Zivo Bioscience with a new price target

    Maxim Group initiated coverage of Zivo Bioscience with a rating of Buy and set a new price target of $9.00

    12/15/21 10:56:47 AM ET
    $ZIVO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ZIVO
    SEC Filings

    View All

    Zivo Bioscience Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

    8-K - Zivo Bioscience, Inc. (0001101026) (Filer)

    12/23/25 4:06:03 PM ET
    $ZIVO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by Zivo Bioscience Inc.

    10-Q - Zivo Bioscience, Inc. (0001101026) (Filer)

    11/14/25 4:39:50 PM ET
    $ZIVO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Zivo Bioscience Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Zivo Bioscience, Inc. (0001101026) (Filer)

    9/10/25 9:49:23 AM ET
    $ZIVO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ZIVO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Cornell Alison A bought $99,995 worth of shares (11,709 units at $8.54), increasing direct ownership by 4% to 279,481 units (SEC Form 4)

    4 - Zivo Bioscience, Inc. (0001101026) (Issuer)

    1/28/26 4:11:45 PM ET
    $ZIVO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    President and CEO Payne John Bernard bought $99,995 worth of shares (11,709 units at $8.54), increasing direct ownership by 148% to 19,618 units (SEC Form 4)

    4 - Zivo Bioscience, Inc. (0001101026) (Issuer)

    1/28/26 4:06:16 PM ET
    $ZIVO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Maggiore Christopher D. bought $14,993 worth of shares (1,766 units at $8.49), increasing direct ownership by 0.34% to 519,292 units (SEC Form 4)

    4 - Zivo Bioscience, Inc. (0001101026) (Issuer)

    1/27/26 5:09:32 PM ET
    $ZIVO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ZIVO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Cornell Alison A bought $99,995 worth of shares (11,709 units at $8.54), increasing direct ownership by 4% to 279,481 units (SEC Form 4)

    4 - Zivo Bioscience, Inc. (0001101026) (Issuer)

    1/28/26 4:11:45 PM ET
    $ZIVO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    President and CEO Payne John Bernard bought $99,995 worth of shares (11,709 units at $8.54), increasing direct ownership by 148% to 19,618 units (SEC Form 4)

    4 - Zivo Bioscience, Inc. (0001101026) (Issuer)

    1/28/26 4:06:16 PM ET
    $ZIVO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Maggiore Christopher D. bought $14,993 worth of shares (1,766 units at $8.49), increasing direct ownership by 0.34% to 519,292 units (SEC Form 4)

    4 - Zivo Bioscience, Inc. (0001101026) (Issuer)

    1/27/26 5:09:32 PM ET
    $ZIVO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ZIVO
    Financials

    Live finance-specific insights

    View All

    ZIVO Bioscience Announces Plans for a New Streamlined, Focused Corporate Structure and Establishes the ZIVOLife Agtech Business

    ZIVOLife to be Granted Exclusive Worldwide Limited License to ZIVO Bioscience Intellectual Property for the Production and Supply of Whole Biomass Algal Products Conference call to be held in early November Zivo Bioscience, Inc. (NASDAQ:ZIVO) (the "Company"), a biotech/agtech R&D company engaged in the development of therapeutic, medicinal and nutritional product candidates derived from proprietary algal cultures, today announced plans to create ZIVOLife LLC ("ZIVOLife"), a newly formed wholly-owned subsidiary, to streamline the Company's corporate structure, better capitalize on the global agtech market opportunity and accelerate progress toward generating revenue from the Company's prop

    10/24/22 4:15:00 PM ET
    $ZIVO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ZIVO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Zivo Bioscience Inc.

    SC 13D/A - Zivo Bioscience, Inc. (0001101026) (Subject)

    10/1/24 2:57:20 PM ET
    $ZIVO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13D filed by Zivo Bioscience Inc.

    SC 13D - Zivo Bioscience, Inc. (0001101026) (Subject)

    6/12/24 8:49:08 PM ET
    $ZIVO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13D filed by Zivo Bioscience Inc.

    SC 13D - Zivo Bioscience, Inc. (0001101026) (Subject)

    6/12/24 8:44:12 PM ET
    $ZIVO
    Biotechnology: Pharmaceutical Preparations
    Health Care